

## MULTISCREEN™ MEMBRANE PREPARATION HUMAN RECOMBINANT P<sub>2</sub>Y<sub>1</sub> RECEPTOR

### PRODUCT INFORMATION

**Catalog Number:** MC1160-3

**Lot Number:** MC1160-3-011426

**Quantity:** 5 mg per vial

**Protein concentration:** 3.6 mg/mL

**Packaging Buffer:** 20mM Gly-Gly, 1 mM MgCl<sub>2</sub>, 25mM Sucrose (pH 7.2)

**Host cell:** 1321N1

**Transfection:** Full-length human P2Y1 cDNA (GenBank Accession Number NM\_002563)


**Recommended Storage:** Liquid nitrogen upon receiving

### Data sheet

**Background:** P2Y1 is a receptor for ATP and ADP. P2Y1 contributes to platelet shape change. A number of P2Y1 receptor-specific antagonists, such as, MRS-2179, A3P5PS, A3P5P and A2P5P have been discovered. They inhibit calcium ion mobilization and shape change in platelets. P2Y1-deficient mice and mice treated with the P2Y1 antagonist MRS2179 displayed significantly less arterial thrombosis than their respective controls. Combination of P2Y1 deficiency with P2Y12 inhibition led to a significant additive effect.

**Application:** Functional assays

#### Figure 1



**Figure 1.** Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.

#### References:

Baurand and Gachet (2003) The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. *Cardiovasc Drug Rev* 21:67-76.

Jin *et al.* (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. *J Biol Chem* 273:2030-2034.

Lenain *et al.* (2003) Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. *J Thromb Haemost* 1:1144-1149.

**FOR RESEARCH USE ONLY.**

Multispan Inc. All rights reserved. No part of this document may be reproduced in any form without prior permission in writing.